Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

Recruiting

Phase 3

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

Sponsor:

Kedrion S.p.A.

Code:

NCT04944979

Conditions

Primary Immunodeficiency Disease

Eligibility Criteria

Sex: All

Age: 2 - 16

Healthy Volunteers: Not accepted

Interventions

Kedrion IVIG 10%

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Kedrion S.p.A. on 2024-11-04.